Skip Navigation

Cardiovascular Research 2000 46(3):606-607; doi:10.1016/S0008-6363(00)00074-2
© 2000 by European Society of Cardiology
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Becker, R.
Right arrow Articles by Schoels, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Becker, R.
Right arrow Articles by Schoels, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Re: ‘Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping’ (Cardiovasc Res 2000;45:310–320)

Ruediger Becker* and Wolfgang Schoels

Department of Cardiology, University of Heidelberg, Bergheimer Strasse 58, 69115 Heidelberg, Germany

* Corresponding author ruediger_becker{at}med.uni-heidelberg.de

Received 23 March 2000; accepted 23 March 2000

KEYWORDS Arrhythmia (mechanisms); Endothelins; Hormones; Mapping; Ventricular arrhythmias

Although the technique of three-dimensional mapping obviously does not provide direct evidence as to whether ET-1-induced ventricular arrhythmias are purely due to ischemia or to a combination of direct electrophysiologic effects and ischemia, we still believe that a number of aspects argue against the hypothesis that ET-1 related arrhythmogenesis is exclusively based on ischemia:

1. The fact that conduction and refractory properties remained entirely unaffected by ET-1.
2. The difference in the mechanism responsible for the maintenance of observed arrhythmias (purely focal vs. focal and reentrant).
3. The occurrence of severe arrhythmias in the presence of a minor degree of coronary blood flow reduction (24–32%), as indicated by previous studies using exactly the same dose of ET-1 [1,2].
4. The observation that bradycardia enhances the arrhythmogenic effect of ET-1 [3], whereas induction rates with programmed ventricular stimulation are low [2].
5. The fact that previous experimental studies failed to demonstrate a correlation between the severity of ischemia and the severity of ET-1-induced ventricular arrhythmias [4]. The predominance of focal arrhythmias originating from the subendocardium in both the ET-1 and the ligation group does not allow the conclusion that ischemia is the mechanism underlying both interventions, because this type of arrhythmia has been shown to be very common in both ischemic [5–7] and nonischemic arrhythmias [8,9].

As far as the potential mechanism underlying the growing prevalence of right ventricular foci with increasing duration of ET-1 infusion is concerned, we believe that recent experimental work supports the hypothesis of a systemic recirculation of ET-1. Although the elimination kinetics of ET-1 are still poorly understood, Parker et al. [10] could demonstrate in healthy individuals that intravenously applied ET-1 has a much longer terminal half life than previously reported. Furthermore, as shown experimentally in rats, plasma endothelin concentration after bolus administration of endothelin is significantly prolonged by bilateral nephrectomy [11]. These data clearly indicate that the pulmonary elimination of endothelin is incomplete and, thus, the endothelin plasma level might well increase with continuous i.v. infusion as applied in our study, although this has not been systematically studied yet.

We are convinced that our study indirectly supports the hypothesis derived from earlier experimental work that, apart from its vasoconstrictive properties, ET-1 exerts primary arrhythmogenic effects. However, further experimental data are required to directly prove this hypothesis.


    References
 Top
 References
 

  1. Toth M., Solti F., Merkely B., et al. Ventricular tachycardias induced by intracoronary administration of endothelin-1 in dogs. J Cardiovasc Pharmacol (1995) 26:S153–S155.[Web of Science][Medline]
  2. Merkely B., Geller L., Toth M., et al. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs. J Cardiovasc Pharmacol (1998) 31(Suppl_1):S437–S439.[CrossRef][Web of Science][Medline]
  3. Toth M., Solti F., Merkely B., et al. Bradycardia enhances the arrhythmogenic effect of endothelin. J Cardiovasc Pharmacol (1998) 31(Suppl I):S431–S433.[CrossRef][Web of Science][Medline]
  4. Salvati P., Chierchia S., Dho L., et al. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional blood flow. J Cardiovasc Pharmacol (1991) 17(6):S1007–S1014.
  5. Janse M.J., Kleber A.G., Capucci A., Coronel R., Wilms-Schopman F. Electrophysiological basis for arrhythmias caused by acute ischemia. J Mol Cell Cardiol (1986) 18:339–355.[CrossRef][Web of Science][Medline]
  6. Pogwizd S.M., Corr P.B. Reentrant and nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: results using three-dimensional mapping. Circ Res (1987) 61:352–371.[Abstract/Free Full Text]
  7. Wu G., Littmann L., Svenson R.H., et al. Computerized three-dimensional activation mapping study of spontaneous ventricular arrhythmias during acute myocardial ischemia in dogs. J Electrocardiol (1995) 28(2):115–130.[CrossRef][Web of Science][Medline]
  8. Pogwizd S.M. Nonreentrant mechanisms underlying spontaneous ventricular arrhythmias in a model of nonischemic heart failure in rabbits. Circulation (1995) 92(4):1034–1048.[Abstract/Free Full Text]
  9. Pogwizd S.M., McKenzie J.P., Cain M.E. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation (1998) 98(22):2404–2414.[Abstract/Free Full Text]
  10. Parker J.D., Thiessen J.J., Reilly R., et al. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther (1999) 289(1):261–265.[Abstract/Free Full Text]
  11. Kohno M., Murakawa K., Yasunari K., et al. Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomized rats. Metabolism (1989) 38(8):712–713.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Becker, R.
Right arrow Articles by Schoels, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Becker, R.
Right arrow Articles by Schoels, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?